TY  - CONF
AU  - Vasiljević, Ivana
AU  - Turković, Erna
AU  - Aleksić, Ivana
AU  - Parojčić, Jelena
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5526
AB  - Introduction: Expert System for Drug Development (SeDeM) was introduced as a method intended for powder processability assessment (1). Its applicability was extended to multiparticulate materials (2-3), but the contribution to liquisolid admixtures/pellets characterization remains to be explored. The aim of this work was to investigate the applicability of SeDeM on liquisolid admixtures/pellets. Methods: Liquisolid admixtures (A) were prepared by manual kneading and subsequently extruded/spheronized into liquisolid pellets (P). ...
C3  - Controlled Release Society: “Breakthrough Delivery Science”, 2021 July 25-29, Virtual Annual Meeting
T1  - Investigation into applicability of Expert System for Drug Development on the model liquisolid systems
UR  - https://hdl.handle.net/21.15107/rcub_farfar_5526
ER  - 

@conference{
author = "Vasiljević, Ivana and Turković, Erna and Aleksić, Ivana and Parojčić, Jelena",
year = "2021",
abstract = "Introduction: Expert System for Drug Development (SeDeM) was introduced as a method intended for powder processability assessment (1). Its applicability was extended to multiparticulate materials (2-3), but the contribution to liquisolid admixtures/pellets characterization remains to be explored. The aim of this work was to investigate the applicability of SeDeM on liquisolid admixtures/pellets. Methods: Liquisolid admixtures (A) were prepared by manual kneading and subsequently extruded/spheronized into liquisolid pellets (P). ...",
journal = "Controlled Release Society: “Breakthrough Delivery Science”, 2021 July 25-29, Virtual Annual Meeting",
title = "Investigation into applicability of Expert System for Drug Development on the model liquisolid systems",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5526"
}

Vasiljević, I., Turković, E., Aleksić, I.,& Parojčić, J.. (2021). Investigation into applicability of Expert System for Drug Development on the model liquisolid systems. in Controlled Release Society: “Breakthrough Delivery Science”, 2021 July 25-29, Virtual Annual Meeting.
https://hdl.handle.net/21.15107/rcub_farfar_5526

Vasiljević I, Turković E, Aleksić I, Parojčić J. Investigation into applicability of Expert System for Drug Development on the model liquisolid systems. in Controlled Release Society: “Breakthrough Delivery Science”, 2021 July 25-29, Virtual Annual Meeting. 2021;.
https://hdl.handle.net/21.15107/rcub_farfar_5526 .

Vasiljević, Ivana, Turković, Erna, Aleksić, Ivana, Parojčić, Jelena, "Investigation into applicability of Expert System for Drug Development on the model liquisolid systems" in Controlled Release Society: “Breakthrough Delivery Science”, 2021 July 25-29, Virtual Annual Meeting (2021),
https://hdl.handle.net/21.15107/rcub_farfar_5526 .

TY  - CONF
AU  - Aleksić, Ivana
AU  - Vasiljević, Ivana
AU  - Glišić, Teodora
AU  - Cvijić, Sandra
AU  - Parojčić, Jelena
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5316
AB  - Liquisolid technology has gained an increased attention as a
promising approach for the improvement of bioavailability
of poorly water soluble drugs. Suitable excipients with high
surface area and porous structure are used to convert liquid
lipophilic drugs or drug solutions/suspensions to powder
suitable for filling into capsules or compression into tablets.
Spireas (1) proposed this approach and pointed out the
importance of selecting the appropriate excipients (carrier
and coating material) in optimum amounts in order to
achieve both good flowability and acceptable compaction
properties, as prerequisites for industrial application.
Compaction properties of liquisolid systems have been
recognized as particularly challenging. However, the
published results regarding compression behavior of
liquisolid systems are still very limited (2, 3).
In the present study mesoporous, amorphous silica
excipients (Syloid® XDP 3050 and XDP 3150), optimized
to be used as carriers in liquisolid systems, were used for
preparation of liquisolid compacts. The aim of this study
was to evaluate the influence of carrier to coating ratio and
liquid content on flowability and compaction behavior of
liquisolid systems prepared with these novel excipients.
PB  - International Association for Pharmaceutical Technology, Mainz, Germany
C3  - 12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, 11th-14th May 2021, Vienna, Austria, Virtual meeting
T1  - Liquisolid systems with mesoporous silica based carriers: An investigation of flow and compaction properties
UR  - https://hdl.handle.net/21.15107/rcub_farfar_5316
ER  - 

@conference{
author = "Aleksić, Ivana and Vasiljević, Ivana and Glišić, Teodora and Cvijić, Sandra and Parojčić, Jelena",
year = "2021",
abstract = "Liquisolid technology has gained an increased attention as a
promising approach for the improvement of bioavailability
of poorly water soluble drugs. Suitable excipients with high
surface area and porous structure are used to convert liquid
lipophilic drugs or drug solutions/suspensions to powder
suitable for filling into capsules or compression into tablets.
Spireas (1) proposed this approach and pointed out the
importance of selecting the appropriate excipients (carrier
and coating material) in optimum amounts in order to
achieve both good flowability and acceptable compaction
properties, as prerequisites for industrial application.
Compaction properties of liquisolid systems have been
recognized as particularly challenging. However, the
published results regarding compression behavior of
liquisolid systems are still very limited (2, 3).
In the present study mesoporous, amorphous silica
excipients (Syloid® XDP 3050 and XDP 3150), optimized
to be used as carriers in liquisolid systems, were used for
preparation of liquisolid compacts. The aim of this study
was to evaluate the influence of carrier to coating ratio and
liquid content on flowability and compaction behavior of
liquisolid systems prepared with these novel excipients.",
publisher = "International Association for Pharmaceutical Technology, Mainz, Germany",
journal = "12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, 11th-14th May 2021, Vienna, Austria, Virtual meeting",
title = "Liquisolid systems with mesoporous silica based carriers: An investigation of flow and compaction properties",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5316"
}

Aleksić, I., Vasiljević, I., Glišić, T., Cvijić, S.,& Parojčić, J.. (2021). Liquisolid systems with mesoporous silica based carriers: An investigation of flow and compaction properties. in 12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, 11th-14th May 2021, Vienna, Austria, Virtual meeting
International Association for Pharmaceutical Technology, Mainz, Germany..
https://hdl.handle.net/21.15107/rcub_farfar_5316

Aleksić I, Vasiljević I, Glišić T, Cvijić S, Parojčić J. Liquisolid systems with mesoporous silica based carriers: An investigation of flow and compaction properties. in 12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, 11th-14th May 2021, Vienna, Austria, Virtual meeting. 2021;.
https://hdl.handle.net/21.15107/rcub_farfar_5316 .

Aleksić, Ivana, Vasiljević, Ivana, Glišić, Teodora, Cvijić, Sandra, Parojčić, Jelena, "Liquisolid systems with mesoporous silica based carriers: An investigation of flow and compaction properties" in 12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, 11th-14th May 2021, Vienna, Austria, Virtual meeting (2021),
https://hdl.handle.net/21.15107/rcub_farfar_5316 .

TY  - JOUR
AU  - Simić, Milena
AU  - Petković, Miloš
AU  - Jovanović, Predrag
AU  - Jovanović, Miloš
AU  - Tasić, Gordana
AU  - Besu, Irina
AU  - Žižak, Željko
AU  - Aleksić, Ivana
AU  - Nikodinović-Runić, Jasmina
AU  - Savić, Vladimir
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3935
AB  - Several coumarin derivatives with a directly attached azole substituent at C‐4 were synthesized and biologically studied for their anticancer properties. The cell lines used for this investigation (HeLa, K‐562, MDA‐MB‐53, and MCF‐7) demonstrated different sensitivities. The best response in the MTT (3‐(4,5‐dimethyl‐2‐thiazolyl)‐ 2,5‐diphenyl‐2H‐tetrazolium bromide) assay was shown by K‐562 cells, with compounds displaying activity (3c, IC50 3.06 μM; 4a, IC50 5.24 μM; 4c, IC50 4.7 μM) similar to that of cisplatin (IC50 ~6 μM), which was used as the standard. The studied azole‐substituted coumarins demonstrated weaker activity toward other cell lines, except for compound 4c, which was equally potent in the case of MCF‐7 cells. Additional biological evaluations supported interference with the cell cycle as a potential mechanism of action and confirmed the absence of toxicity in zebrafish embryos. On the basis of these initial results, 4‐azole coumarins should be explored further. Although their activity would need additional optimization, the fact that these compounds are fragment‐like structures with MW <300 and clog P <3 offers enough flexibility to fine‐tune their drug‐like properties.
PB  - John Wiley and Sons Inc
T2  - Archiv der Pharmazie
T1  - Fragment-type 4-azolylcoumarin derivatives with anticancer properties
DO  - 10.1002/ardp.202100238
ER  - 

@article{
author = "Simić, Milena and Petković, Miloš and Jovanović, Predrag and Jovanović, Miloš and Tasić, Gordana and Besu, Irina and Žižak, Željko and Aleksić, Ivana and Nikodinović-Runić, Jasmina and Savić, Vladimir",
year = "2021",
abstract = "Several coumarin derivatives with a directly attached azole substituent at C‐4 were synthesized and biologically studied for their anticancer properties. The cell lines used for this investigation (HeLa, K‐562, MDA‐MB‐53, and MCF‐7) demonstrated different sensitivities. The best response in the MTT (3‐(4,5‐dimethyl‐2‐thiazolyl)‐ 2,5‐diphenyl‐2H‐tetrazolium bromide) assay was shown by K‐562 cells, with compounds displaying activity (3c, IC50 3.06 μM; 4a, IC50 5.24 μM; 4c, IC50 4.7 μM) similar to that of cisplatin (IC50 ~6 μM), which was used as the standard. The studied azole‐substituted coumarins demonstrated weaker activity toward other cell lines, except for compound 4c, which was equally potent in the case of MCF‐7 cells. Additional biological evaluations supported interference with the cell cycle as a potential mechanism of action and confirmed the absence of toxicity in zebrafish embryos. On the basis of these initial results, 4‐azole coumarins should be explored further. Although their activity would need additional optimization, the fact that these compounds are fragment‐like structures with MW <300 and clog P <3 offers enough flexibility to fine‐tune their drug‐like properties.",
publisher = "John Wiley and Sons Inc",
journal = "Archiv der Pharmazie",
title = "Fragment-type 4-azolylcoumarin derivatives with anticancer properties",
doi = "10.1002/ardp.202100238"
}

Simić, M., Petković, M., Jovanović, P., Jovanović, M., Tasić, G., Besu, I., Žižak, Ž., Aleksić, I., Nikodinović-Runić, J.,& Savić, V.. (2021). Fragment-type 4-azolylcoumarin derivatives with anticancer properties. in Archiv der Pharmazie
John Wiley and Sons Inc..
https://doi.org/10.1002/ardp.202100238

Simić M, Petković M, Jovanović P, Jovanović M, Tasić G, Besu I, Žižak Ž, Aleksić I, Nikodinović-Runić J, Savić V. Fragment-type 4-azolylcoumarin derivatives with anticancer properties. in Archiv der Pharmazie. 2021;.
doi:10.1002/ardp.202100238 .

Simić, Milena, Petković, Miloš, Jovanović, Predrag, Jovanović, Miloš, Tasić, Gordana, Besu, Irina, Žižak, Željko, Aleksić, Ivana, Nikodinović-Runić, Jasmina, Savić, Vladimir, "Fragment-type 4-azolylcoumarin derivatives with anticancer properties" in Archiv der Pharmazie (2021),
https://doi.org/10.1002/ardp.202100238 . .

TY  - JOUR
AU  - Aleksić, Ivana
AU  - Petković, Miloš
AU  - Jovanović, Miloš
AU  - Milivojević, Dušan
AU  - Vasiljević, Branka
AU  - Nikodinović-Runić, Jasmina
AU  - Senerović, Lidija
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2858
AB  - A new strain, namely Lysinibacillus sp. BV152.1 was isolated from the rhizosphere of ground ivy (Glechoma hederacea L.) producing metabolites with potent ability to inhibit biofilm formation of an important human pathogens Pseudomonas aeruginosa PAO1, Staphylococcus aureus, and Serratia marcescens. Structural characterization revealed di-rhamnolipids mixture containing rhamnose (Rha)-Rha-C10-C10, Rha-Rha-C8-C10, and Rha-Rha-C10-C12 in the ratio 7: 2: 1 as the active principle. Purified di-rhamnolipids, as well as commercially available di-rhamnolipids (Rha-Rha-C10-C10, 93%) were used as the substrate for the chemical derivatization for the first time, yielding three semisynthetic amide derivatives, benzyl-, piperidine-, and morpholine. A comparative study of the anti-biofilm, antibacterial and cytotoxic properties revealed that di-Rha from Lysinibacillus sp. BV152.1 were more potent in biofilm inhibition, both cell adhesion and biofilm maturation, than commercial di-rhamnolipids inhibiting 50% of P. aeruginosa PAO1 biofilm formation at 50 mu g mL(-1) and 75 mu g mL(-1), respectively. None of the dirhamnolipids exhibited antimicrobial properties at concentrations of up to 500 mu g mL(-1). Amide derivatization improved inhibition of biofilm formation and dispersion activities of di-rhamnolipids from both sources, with morpholine derivative being the most active causing more than 80% biofilm inhibition at concentrations 100 mu g mL(-1). Semisynthetic amide derivatives showed increased antibacterial activity against S. aureus, and also showed higher cytotoxicity. Therefore, described di-rhamnolipids are potent anti-biofilm agents and the described approach can be seen as viable approach in reaching new rhamnolipid based derivatives with tailored biological properties.
PB  - Frontiers Media Sa, Lausanne
T2  - Frontiers in Microbiology
T1  - Anti-biofilm Properties of Bacterial Di-Rhamnolipids and Their Semi-Synthetic Amide Derivatives
VL  - 8
DO  - 10.3389/fmicb.2017.02454
ER  - 

@article{
author = "Aleksić, Ivana and Petković, Miloš and Jovanović, Miloš and Milivojević, Dušan and Vasiljević, Branka and Nikodinović-Runić, Jasmina and Senerović, Lidija",
year = "2017",
abstract = "A new strain, namely Lysinibacillus sp. BV152.1 was isolated from the rhizosphere of ground ivy (Glechoma hederacea L.) producing metabolites with potent ability to inhibit biofilm formation of an important human pathogens Pseudomonas aeruginosa PAO1, Staphylococcus aureus, and Serratia marcescens. Structural characterization revealed di-rhamnolipids mixture containing rhamnose (Rha)-Rha-C10-C10, Rha-Rha-C8-C10, and Rha-Rha-C10-C12 in the ratio 7: 2: 1 as the active principle. Purified di-rhamnolipids, as well as commercially available di-rhamnolipids (Rha-Rha-C10-C10, 93%) were used as the substrate for the chemical derivatization for the first time, yielding three semisynthetic amide derivatives, benzyl-, piperidine-, and morpholine. A comparative study of the anti-biofilm, antibacterial and cytotoxic properties revealed that di-Rha from Lysinibacillus sp. BV152.1 were more potent in biofilm inhibition, both cell adhesion and biofilm maturation, than commercial di-rhamnolipids inhibiting 50% of P. aeruginosa PAO1 biofilm formation at 50 mu g mL(-1) and 75 mu g mL(-1), respectively. None of the dirhamnolipids exhibited antimicrobial properties at concentrations of up to 500 mu g mL(-1). Amide derivatization improved inhibition of biofilm formation and dispersion activities of di-rhamnolipids from both sources, with morpholine derivative being the most active causing more than 80% biofilm inhibition at concentrations 100 mu g mL(-1). Semisynthetic amide derivatives showed increased antibacterial activity against S. aureus, and also showed higher cytotoxicity. Therefore, described di-rhamnolipids are potent anti-biofilm agents and the described approach can be seen as viable approach in reaching new rhamnolipid based derivatives with tailored biological properties.",
publisher = "Frontiers Media Sa, Lausanne",
journal = "Frontiers in Microbiology",
title = "Anti-biofilm Properties of Bacterial Di-Rhamnolipids and Their Semi-Synthetic Amide Derivatives",
volume = "8",
doi = "10.3389/fmicb.2017.02454"
}

Aleksić, I., Petković, M., Jovanović, M., Milivojević, D., Vasiljević, B., Nikodinović-Runić, J.,& Senerović, L.. (2017). Anti-biofilm Properties of Bacterial Di-Rhamnolipids and Their Semi-Synthetic Amide Derivatives. in Frontiers in Microbiology
Frontiers Media Sa, Lausanne., 8.
https://doi.org/10.3389/fmicb.2017.02454

Aleksić I, Petković M, Jovanović M, Milivojević D, Vasiljević B, Nikodinović-Runić J, Senerović L. Anti-biofilm Properties of Bacterial Di-Rhamnolipids and Their Semi-Synthetic Amide Derivatives. in Frontiers in Microbiology. 2017;8.
doi:10.3389/fmicb.2017.02454 .

Aleksić, Ivana, Petković, Miloš, Jovanović, Miloš, Milivojević, Dušan, Vasiljević, Branka, Nikodinović-Runić, Jasmina, Senerović, Lidija, "Anti-biofilm Properties of Bacterial Di-Rhamnolipids and Their Semi-Synthetic Amide Derivatives" in Frontiers in Microbiology, 8 (2017),
https://doi.org/10.3389/fmicb.2017.02454 . .